|
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
RECRUITINGSponsored by University Hospital, Strasbourg, France
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2024-04-22
Est. completion2025-12-22
Eligibility
Age18 Years+
SexFEMALE
View on ClinicalTrials.gov →
NCT06907771
Summary
Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.
Eligibility
Age: 18 Years+Sex: FEMALE
Inclusion Criteria: * Adult patient (≥18 years old) * Operated on at the HUS between January 1, 2010 and December 31, 2022 * Having undergone primary or interval cytoreductive surgery * Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin Exclusion Criteria: * Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques. * Autres types histologiques de cancer de l'ovaire * Stades de la maladie FIGO I, II, IIIA et IIIC * Chirurgie de clôture.
Conditions2
CancerOvarian Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2024-04-22
Est. completion2025-12-22
Eligibility
Age18 Years+
SexFEMALE
View on ClinicalTrials.gov →
NCT06907771